Table 2. CTCs in the cases with carcinoma in situ.
| PMID | Tumor type | Case(n) | Test Time | Cell isolation/ confirmation | Marker | CTC | Prognosis |
|---|---|---|---|---|---|---|---|
| 21264346 | breast cancer In situ | 73 | 3wto 5y after surgery | Cell Search® | EpCAMHER2 | Positive in 4.1%patients | N.A. |
| 21207426 | breast cancer In situ | 30 | At the time of surgery before tumor excision | Immuno-cyto-chemical assay | CKs | DTCs-positive in 21.1% patients | DTC+ patients had Relapse or metastasis |
| 20535130 | melanoma in situ | 17 | Pre-operatively | ISET (ScreenCell®)/RT-PCR | Tyro-sinase | 0% | N.A. |
| 20651396 | breast cancer in situ | 12 | At the time of diagnosis | Ficoll-Hipaque (Biochrome AG, Germany)/RT-PCR | hMAM | 0 | N.A. |
| 22351740 | bladder cancer In situ | 8 | At the first time of diagnosis | Cell Search® | EpCAM CKs | Positive in 62.5%patients | CTC+ cases: shorter time to recurrence |
| 23088337 | breast cancer Insitu | 48 | Pre-operatively | Cell Search® | EpCAM CKs | Positive in 18.7% patients | N.A. |
Note: CKs: cytokeratins; DTCs: disseminated tumor cells in bone marrow; EpCAM: epithelial cell adhesion molecule; HER2: human epidermal growth factor receptor-2; hMAM: human mammaglobin; N.A. not addressed.